AFT Pharmaceuticals Limited (AFP.AX)

AFT Pharmaceuticals Limited (AFP.AX) — VMCI valuation read

AFP.AX screens at VMCI 46/100, a 4-point gap below the Healthcare sector median (50). For a mid-cap AFT Pharmaceuticals Limited share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

AFP.AX has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: AFP.AX trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 0.1x leaves covenant headroom, which sets the rate-cycle exposure for AFT Pharmaceuticals Limited.

AFP.AX rose 2.5% over the trailing 7 days, with a -11.2% read on a 30-day basis.